Abstract Details

Title Cannabis use by Patients with Multiple Sclerosis in Colorado

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-092

Objective To explore cannabis use among patients with multiple sclerosis (PwMS) treated at a large academic medical center in a state where cannabis is legal. Specifically, we examined: 1) prevalence of use, 2) patient characteristics of cannabis users (CUs) and non-users (NUs; e.g., demographics, disability status), 3) symptoms cannabis is used to manage, and 4) cannabis products used (e.g., combustable vs. edible).

Background Studies suggest that cannabis may be useful for the management of symptoms like pain and muscle spasticity. However, few studies have explored the profile of PwMS who are CUs and the characteristics of their use, particularly in a state where cannabis is legal recreationally and medicinally

Design/Methods PwMS completed a questionnaire via tablet computer assessing personal opinions about cannabis use, characteristics of cannabis use, sociodemographics, and MS history, as well as the Patient Determined Disease Steps (PDDS), Patient Reported Outcome Measure Information System (PROMIS-10), and Neuro-QoL ACGC v1.0 measures.

Results Of 251 respondents, 38% were current CUs. No sociodemographic differences between CUs and NUs were found (p > 0.05), but CUs reported significantly higher disability compared to NUs on the PDDS (p ≤ 0.05). Among CUs, 57% categorized their use as strictly medicinal. Among strictly medicinal CUs, 91% use products that are not combusted/smoked and 83% reported using products with at least some CBD (vs. only THC). Strictly medicinal CUs also had significantly reduced self-reported physical health on the PROMIS-10 (p ≤ 0.05) and higher reported disability on the PDDS (p ≤ 0.01). CUs reported using cannabis most often to manage pain and insomnia, with 79% reporting that they experience no side-effects.

Conclusions

Legalization efforts appear to be increasing the number of PwMS seeking out cannabis as a complimentary-alternative medicine, with CUs self-reporting that their products of choice are highly efficacious and noting minimal side-effects.

Authors/Disclosures
Christopher Domen PRESENTER	Christopher Domen has nothing to disclose.
Laura J Weinkle, MS (University of Colorado: Anschutz Medical Campus)	No disclosure on file
	No disclosure on file
Stefan Sillau	Stefan Sillau has nothing to disclose.
Kavita Nair, PhD, FAAN (University of Colorado)	Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for PhRMA Foundation. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MJH Lifesciences. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anylam . Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Applied Patient Experience. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Esai. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MHJ Life Sciences. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi-Genzyme. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for ICER. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Phrma Foundation. The institution of Dr. Nair has received research support from Bristol Meyers Squibb. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from NINDS. The institution of Dr. Nair has received research support from Sanofi Genzyme. The institution of Dr. Nair has received research support from Kyverna Therapeutcis. Dr. Nair has a non-compensated relationship as a Board Member with Center for Improving Value in Healthcare that is relevant to AAN interests or activities.
Enrique Alvarez, MD, PhD (University of Colorado)	Dr. Alvarez has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Alvarez has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Alvarez has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene/BMS. The institution of an immediate family member of Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon.

��ɫ��

��ɫ��